Peter G. Milner, MD, FACC

Chairman

Dr. Milner is an experienced physician, researcher and biomedical entrepreneur. His history and leadership in the industry enables him to provide powerful insights for AshHill Biomedical Investments and its portfolio companies.

In 2007, Dr. Milner co-founded Optivia Biotechnology, a private company now recognized as a leader in the emerging field of transporter biology. Prior to that, he co-founded ARYx Therapeutics (NASDAQ:ARYX) in 1997, where he served as CEO until 2005 and President from 2005 to 2010 with overall responsibility for R&D.  In 1990, he co-founded CV Therapeutics (NASDAQ:CVTX), where as a member of senior management, he in-licensed and co-invented several successful pharmaceuticals. CV Therapeutics was acquired by Gilead for $1.5B in cash in 2009.

In addition to these ventures, in 2005, Dr. Milner was instrumental in restructuring his family pharmaceutical company ML Laboratories (MLB.LSE) and its subsequent merger to form Vectura (VEC.LSE), a profitable company and one of the world’s leading makers of inhaled products.

Prior to 1992, Dr. Milner was as an assistant professor of medicine at Washington University in St. Louis. His research led to the discovery of pleiotrophin (PTN), a novel growth factor that regulates stem cell differentiation, organ development and the epithelial mesenchymal transition (EMT).

He was educated at the University of Liverpool, receiving his medical degree in 1980, before completing his postgraduate training at Johns Hopkins Hospital, The University of Virginia and Washington University in St. Louis.

Dr. Milner is co-inventor on 48 issued patents and the author of 28 original scientific articles in Science, Biochemistry, Circulation, Cancer, JCI, and JBC. He is a Fellow of the American College of Cardiology (FACC), and a board-certified physician and cardiologist. He serves as a part of the adjunct clinical faculty at Stanford University School of Medicine and as a board member of the California Healthcare Institute.


AshHill Biomedical Portfolio:

  • Chairman of the Board at Armetheon
  • Board Member of SinuSys